Although the overall status of histone modification is largely unknown in PAH, nuclear or pan-HDAC inhibitors have also been exploited in PAH for their beneficial effects under several pathophysiological conditions like cancer and inflammation36. Here, HDAC9 is linked to pulmonary arterial hypertension.